Global Peptic Ulcer Drugs Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Global Peptic Ulcer Drugs Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Peptic Ulcer Drugs market size was valued at US$ 18720 million in 2024 and is forecast to a readjusted size of USD 24090 million by 2031 with a CAGR of 3.7% during review period.

Peptic ulcer drugs are medications specifically designed to treat and manage peptic ulcers, which are sores that develop on the lining of the stomach, small intestine, or esophagus due to the erosion caused by stomach acid. These drugs work by reducing stomach acid production, protecting the stomach lining, or eradicating the bacteria Helicobacter pylori, which is commonly associated with ulcer formation. The main classes of peptic ulcer drugs include proton pump inhibitors (PPIs), such as omeprazole and esomeprazole, which effectively lower acid secretion by inhibiting the proton pumps in the stomach lining. H2-receptor antagonists, like ranitidine and famotidine, also reduce acid production by blocking histamine receptors on acid-producing cells. Additionally, antacids neutralize existing stomach acid to provide immediate relief from ulcer-related symptoms. Other medications, such as sucralfate, create a protective barrier over the ulcer to aid healing, and antibiotics are used in combination therapies to eradicate H. pylori. These drugs play a crucial role in alleviating symptoms, promoting healing, and preventing ulcer recurrence, significantly improving the quality of life for individuals suffering from peptic ulcers.

The main global Peptic Ulcer Drugs players include Takeda Pharmaceutical, AstraZeneca, Pfizer, Teva Pharmaceuticals, EA Pharma, etc. The top five Peptic Ulcer Drugs players account for approximately 43% of the total market. United States is the largest consumer market for Peptic Ulcer Drugs, accounting for about 30%, followed by Europe and China. In terms of type, Proton Pump Inhibitors is the largest segment, with a share over 68%. And in terms of application, the largest application is Hospital and Clinic, followed by Drugstore.

The market for peptic ulcer drugs is evolving rapidly, driven by advancements in treatment options, increasing prevalence of gastrointestinal disorders, and a growing focus on personalized medicine. Proton pump inhibitors (PPIs) continue to dominate the market due to their efficacy in reducing stomach acid production and promoting ulcer healing. However, there is a notable shift towards exploring alternative therapies and combination treatments to address issues such as antibiotic resistance and long-term PPI use side effects. H2-receptor antagonists remain relevant, especially for patients who experience fewer side effects or need cost-effective solutions.

Recent trends highlight a growing interest in novel drug formulations and over-the-counter (OTC) options, as well as an increased emphasis on targeted therapies that address specific causes of ulcers, such as Helicobacter pylori infection. The market is also seeing innovations in drug delivery systems and adjunctive therapies designed to enhance treatment outcomes and patient compliance. Furthermore, rising awareness and diagnostic advancements are contributing to early detection and management of peptic ulcers, further driving market growth.



This report is a detailed and comprehensive analysis for global Peptic Ulcer Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Peptic Ulcer Drugs market size and forecasts, in consumption value ($ Million), 2020-2031

Global Peptic Ulcer Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Peptic Ulcer Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Peptic Ulcer Drugs market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Peptic Ulcer Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Peptic Ulcer Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Livzon Pharmaceutical, Jiangsu Aosaikang Pharmaceutical, CTTQ, Luoxin Pharmaceuticals, Takeda, Eisai, Jumpcan Pharmaceutical, Zhejiang Conba Pharmaceutical, Youcare Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Peptic Ulcer Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Proton Pump Inhibitors
H2-Antagonists
Antacids
Others

Market segment by Application
Hospital and Clinic
Drugstore

Market segment by players, this report covers
AstraZeneca
Livzon Pharmaceutical
Jiangsu Aosaikang Pharmaceutical
CTTQ
Luoxin Pharmaceuticals
Takeda
Eisai
Jumpcan Pharmaceutical
Zhejiang Conba Pharmaceutical
Youcare Pharmaceutical
Chongqing Lummy Pharmaceutical
Huadong Medicine
Hansoh Pharmaceutical
CR Double-Crane
Hunan Warrant Pharmaceutical
Changzhou Siyao Pharmaceuticals
Chongqing Pharscin Pharmaceutical
Lionco Pharmaceutical
Jiangsu Wuzhong Pharmaceutical
Cisen Pharmaceutical

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Peptic Ulcer Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Peptic Ulcer Drugs, with revenue, gross margin, and global market share of Peptic Ulcer Drugs from 2020 to 2025.

Chapter 3, the Peptic Ulcer Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Peptic Ulcer Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Peptic Ulcer Drugs.

Chapter 13, to describe Peptic Ulcer Drugs research findings and conclusion.